Corporate News
Chugai Pharmaceutical Co., Ltd. reported a stronger first‑half performance for 2026, with earnings and revenue rising largely on the back of increased sales of its core and new products. The company highlighted growth in domestic and overseas markets, driven by stronger demand for established therapies such as Vabysmo, Polivy, Enspryng, Phesgo and the newly launched Elevidys and Lunsumio. Export sales of Hemlibra to Roche and NEMLUVIO to Galderma also contributed to the overall uplift.
The Japanese drug maker reaffirmed its guidance for the full year, projecting continued sales growth and solid core earnings. It also confirmed expectations for a moderate dividend increase, with the total payout lower than the previous year’s level.
Overall, the update underscored Chugai’s solid momentum in both its domestic and international business segments and its confidence in the 2026 outlook.
